AEterna Zentaris sells Cetrotide royalty stream
This article was originally published in Scrip
AEterna Zentaris is selling its royalty stream from Cetrotide (cetrorelix) to Cowen Healthcare Royalty Partners for $52.5 million. The royalties are based on sales of drug in in vitro fertilisation (IVF) and AEterna is entitled to an additional $2.5 million upon reaching a specific level of net sales in 2010. AEterna will use the cash primarily to fund the development of cetrorelix, which is in Phase III clinical trials in Europe and North America for the treatment of benign prostatic hyperplasia. The firm expects results in the third quarter of 2009 and will seek a commercial partner for the compound. Cetrotide is the first luteinising hormone-releasing hormone antagonist treatment for IVF. The compound helps to prevent premature ovulation in order to increase fertility success. Merck Serono markets Cetrotide in this indication worldwide, with the exception of Japan, under a 2000 licence from AEterna. If the drug is approved in an indication other than IVF, AEterna will pay a one-off fee of $5-15 million to Cowen. AEterna expects to end 2008 with around $50 million in cash.
You may also be interested in...
AB Science has closed its IPO at just half of the value of its initial expectations. The gross proceeds of the French firm's offer were €27.5 million, compared with the €55.5 million it anticipated when it filed for the offering on 8 April. Of the total, the company secured $16.5 million from the sale of newly issued shares; the remaining €11 million went to selling shareholders.
Amgen's sales rebounded in the first quarter rising 9% to $3.6 billion after a disappointing end to last year. However, the introduction of new legislation for US healthcare has weighed on its forecast for the year, as it has done for many of its competitors.
Actelion's total revenues leapt up by 24% to CHF502 million ($467 million) during the first quarter due to stronger demand for its pharmaceuticals. The firm's net income rose by 30% to CHF133 million, while its diluted EPS increased from CHF0.83 in the first quarter last year to CHF1.09.